The global Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 2,893.3 million by 2028 according to a new study by Polaris Market Research. The report “iPSC Market Share, Size, Trends, Industry Analysis Report By Application (Manufacturing, Academic Research, Drug Development & Discovery, Toxicity Screening, Regenerative Medicine); By Derived Cell; By Region, Segment & Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The ability to model human diseases in vitro as well as high-throughput screening has greatly propelled market growth. Companies have effectively overcome market hurdles faced in the recent past such as proper culturing and differentiation of derived cells at a commercial scale and have developed state-of-the-art manufacturing processes that can achieve scalability and can achieve stringent quality parameters. Such trends are propelling the overall industry growth.
Companies have also developed advanced platforms for Induced pluripotent stem cells that guarantee close connection with a host of in-house technologies that are useful in the proper definition of disease signatures as well as relationships between genetic mutations as well as that properly describe perturbation of specific molecular pathways. This has resulted in the creation of human translational models that are aiding better target identification of diseases that have high unmet medical needs.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/induced-pluripotent-stem-cell-ipsc-market/request-for-sample
Many companies have developed transfection kits, reprogramming vectors, differentiation media, live staining kits, immunocytochemistry, among others to aid the smooth workflow of iPSC production. However, it has been observed in the recent past that the demand for cells for screening and other purposes is significant and that there are significant challenges that pose a significant hurdle in large-scale iPSC production and differentiation.
Heavy investment in R&D activities pertaining to the development and optimization of iPSC reprogramming process in order to achieve sufficient production is a key industry trend. In the recent past, companies focused more on hepatic, cardiac, pancreatic cells, among others. However, with the advent of a number of new participants as well as advancements and breakthroughs achieved, it is anticipated that the application portfolio will further increase in the near future.
Industry participants such as Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation (Cellular Dynamics), Takara Bio Inc, Astellas Pharma Inc., Fate Therapeutics, Axol Bioscience Ltd., Cynata Therapeutics Limited, Ncardia, REPROCELL USA, Inc., ViaCyte, Inc., among others, are some of the key players operating in the industry.
Polaris Market Research has segmented the iPSC market report on the basis of derived cell, application, and region:
iPSC, Derived Cell Outlook (Revenue, USD Million, 2017 – 2028)
- Amniotic Cells
iPSC, Application Outlook (Revenue, USD Million, 2017 – 2028)
- Academic Research
- Drug Development And Discover
- Toxicity Screening
- Regenerative Medicine
iPSC Regional Outlook (Revenue, USD Million, 2017 – 2028)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa